Laurent Chardonnet
Chief Financial Officer at Prelude Therapeutics Incorporated - Wilmington, DE, US
Laurent Chardonnet's Colleagues at Prelude Therapeutics Incorporated
Rachel Chiaverelli
Director, Translational Medicine/Clinical Biomarker Lead
Laurent Chardonnet's Contact Details
302-467-1280
Prelude Therapeutics Incorporated
Laurent Chardonnet's Company Details
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company's lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude's first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme. The Company's pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.